BiotechTube

4mg CLS-TA Suprachoriodal Injection + Sham Procedure

Phase 3Completed
0 views this week 0 watching💤 Quiet
Interest: 30/100
30
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Uveitis

Conditions

Uveitis, Uveitis, Posterior, Uveitis, Anterior, Uveitis, Intermediate, Panuveitis

Trial Timeline

Nov 17, 2015 → Jan 18, 2018

NCT ID
NCT02595398

About 4mg CLS-TA Suprachoriodal Injection + Sham Procedure

4mg CLS-TA Suprachoriodal Injection + Sham Procedure is a phase 3 stage product being developed by Clearside Biomedical for Uveitis. The current trial status is completed. This product is registered under clinical trial identifier NCT02595398. Target conditions include Uveitis, Uveitis, Posterior, Uveitis, Anterior.

What happened to similar drugs?

3 of 20 similar drugs in Uveitis were approved

Approved (3) Terminated (8) Active (9)
✅Ixekizumab Prefilled SyringeEli LillyApproved
✅AdalimumabAbbVieApproved
✅Topical Prednisolone Acetate 1%Ocular TherapeutixApproved
🔄4 mg CLS-TA Suprachoriodal InjectionClearside BiomedicalPhase 3
🔄Baricitinib + AdalimumabEli LillyPhase 3
🔄adalimumabAbbViePhase 3
🔄Adalimumab + Prednisone + PlaceboAbbViePhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02595398Phase 3Completed

Competing Products

20 competing products in Uveitis

See all competitors
ProductCompanyStageHype Score
triamcinolone acetonide (Triesence®)Clearside BiomedicalPhase 1/2
22
4 mg CLS-TA Suprachoriodal InjectionClearside BiomedicalPhase 3
30
Baricitinib + AdalimumabEli LillyPhase 3
44
Ixekizumab Prefilled SyringeEli LillyApproved
39
adalimumabAbbViePhase 3
40
Adalimumab + Prednisone + PlaceboAbbViePhase 3
40
Adalimumab + Prednisone + PlaceboAbbViePhase 3
40
AdalimumabAbbVieApproved
43
FTY720 + Oral CorticosteroidNovartisPhase 2
27
AIN457NovartisPhase 3
32
MyforticNovartisPre-clinical
22
AIN457 + AIN457 + Placebo AIN457NovartisPhase 3
32
LFG316 + Conventional TherapyNovartisPhase 2
35
RanibizumabNovartisPhase 2
35
AIN457 + PlaceboNovartisPhase 3
32
AIN457 + AIN457 + AIN457 + PlaceboNovartisPhase 3
32
AEB071NovartisPhase 2
35
AIN457 + AIN457 + AIN457 + PlaceboNovartisPhase 3
32
Myfortic + DecortinNovartisPhase 3
40
AIN457 + AIN 457 + AIN457NovartisPhase 2
35